Innovent Reports Updates on the P-I Evaluation of IBI3002 for the Treatment of Asthma
Shots:
- The company has dosed the 1st patient with IBI3002 in Australia under the P-I first-in-human clinical evaluation
- The P-I clinical trial evaluating the safety, tolerability, PK & PD of IBI3002 vs PBO in healthy individuals & in patients with mild-to-moderate asthma
- IBI3002 is a humanized bispecific Ab that functions by targeting the cell surface IL-4Rα and the alarmin cytokine TSLP
Ref: PR Newswire | Image: Innovent
Related News:- Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
